Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200710 | 0.83 | FOLH1 (0.54) | FOLH1KMT2ADPP4CA12CA1 | |
| SCHEMBL28634056 | 0.81 | HSD17B10 (0.63) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL7262126 | 0.79 | HSD17B10 (0.76) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL30387687 | 0.79 | HSD17B10 (0.76) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL30013531 | 0.79 | HSD17B10 (0.76) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL5697861 | 0.78 | DPP4 (0.41) | HSD17B10DPP4ALOX5ALDH1A1KDM4E | |
| SCHEMBL20488085 | 0.77 | HSD17B10 (0.73) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL31506351 | 0.77 | HSD17B10 (0.68) | HSD17B10FOLH1MEN1KMT2ACA12 | |
| SCHEMBL21803820 | 0.76 | TTR (0.51) | FOLH1MEN1KMT2ADPP4ALDH1A1 | |
| SCHEMBL27884269 | 0.76 | ESR2 (0.53) | MEN1KMT2ADPP4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1222163-B1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-07-12 | — | — | EP | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-6686395-B2 | THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6531495-B1 | Potassium channel | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-1222163-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025189-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | HSD17B10 3045/4885FOLH1 3727/4885MEN1 3516/4885 |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | HSD17B10 3061/4885FOLH1 3699/4885MEN1 3547/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | HSD17B10 3065/4885FOLH1 3729/4885MEN1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.